Valuation: Cutia Therapeutics

Market Cap 24Cr 28Cr 3.57Cr 3.17Cr 2.94Cr 2.67Cr 5.01Cr 337.82Cr 5.09Cr 35Cr 14Cr 176.79Cr 13Cr 13Cr 563.97Cr P/E 2026 *
21.3x
P/E 2027 * 4.56x
Enterprise Value 24Cr 28Cr 3.57Cr 3.17Cr 2.94Cr 2.67Cr 5.01Cr 337.82Cr 5.09Cr 35Cr 14Cr 176.79Cr 13Cr 13Cr 563.97Cr EV / Sales 2026 *
0.41x
EV / Sales 2027 * 0.25x
Free-Float
32.87%
Yield 2026 *
-
Yield 2027 * -
1 day-7.33%
1 week+1.46%
Current month-31.86%
1 month-41.60%
3 months-73.37%
6 months-85.49%
Current year-84.69%
1 week 0.6
Extreme 0.6
0.88
1 month 0.6
Extreme 0.6
1.33
Current year 0.6
Extreme 0.6
5.51
1 year 0.6
Extreme 0.6
8.38
3 years 0.6
Extreme 0.6
24
5 years 0.6
Extreme 0.6
32.6
10 years 0.6
Extreme 0.6
32.6
Manager TitleAgeSince
Chief Executive Officer 48 01/09/2019
Chief Tech/Sci/R&D Officer 54 09/09/2019
Corporate Secretary 45 28/08/2025
Director TitleAgeSince
Director/Board Member 48 12/05/2020
Chairman 63 23/08/2019
Director/Board Member 45 23/08/2019
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Other

Chief Financial Officer

-2,10,847 0.0563%
28/09/26 Other

Founder

-13,02,800 0.3478%
25/09/26 Other

Founder

-91,000 0.0243%
Change 5-day change 1-year change 3-year change Capi.($)
-7.33%+1.46%-91.66%-96.56% 3.57Cr
+3.49%+10.04%+58.68%+119.56% 1,14400Cr
+2.19%+4.32%+33.88%+69.52% 63TCr
+2.26%+5.37%+24.57%+97.69% 51TCr
+2.58%+8.37%+38.71%+63.14% 38TCr
+3.25%+4.45%+71.80%+44.44% 37TCr
+1.85%+6.04%+21.47%+49.17% 29TCr
+1.76%+6.07%+0.43%+20.98% 26TCr
+3.29%+6.32%+44.71%+57.43% 24TCr
+2.25%+5.81%+27.13%+101.17% 19TCr
Average +1.11%+3.83%+22.97%+52.65% 40.08TCr
Weighted average by Cap. +1.43%+4.68%+40.92%+80.67%

Financials

2026 *2027 *
Net sales 59Cr 69Cr 8.8Cr 7.84Cr 7.26Cr 6.58Cr 12Cr 833.9Cr 13Cr 87Cr 34Cr 436.39Cr 33Cr 32Cr 1.39TCr 96Cr 112.91Cr 14Cr 13Cr 12Cr 11Cr 20Cr 1.36TCr 21Cr 142.41Cr 56Cr 713.22Cr 54Cr 53Cr 2.28TCr
Net income 1Cr 1.17Cr 14.97L 13.33L 12.35L 11.19L 21.03L 14Cr 21.38L 1.48Cr 58.21L 7.42Cr 56.15L 54.99L 24Cr 5Cr 5.87Cr 74.85L 66.63L 61.75L 55.95L 1.05Cr 71Cr 1.07Cr 7.41Cr 2.91Cr 37Cr 2.81Cr 2.75Cr 118.38Cr
Net Debt - -
Projected Income Statement - Annual - Cutia Therapeutics
Logo Cutia Therapeutics
Cutia Therapeutics is an investment holding company principally engaged in the dermatology biopharmaceutical business. The Company is dedicated to developing solutions in the dermatology treatment and care market, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management. The Company is primarily engaged in the distribution of scalp diseases and care products, as well as certain skin care products. The Company's principal pipeline products include topical finasteride spray CU-40102, topical 4% minocycline foam CU-10201, topical novel small molecule agent CU-10101, localized topical lidocaine and tetracaine cream CU-30101 and recombinant mutant collagenase CU-20401.
Employees
268
Date Price Change Volume
21/26/21 HK$0.6950 -7.33% 3,83,600
20/26/20 HK$0.7500 -12.79% 5,55,000
16/26/16 HK$0.8600 +28.36% 17,43,400
15/26/15 HK$0.6700 -2.19% 45,94,200
14/26/14 HK$0.6850 -6.80% 44,70,200
Trader
-
Investor
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - Cutia Therapeutics
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6383CNY
Average target price
6.572CNY
Spread / Average Target
+929.58%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Cutia Therapeutics
  1. Stock Market
  2. Stocks
  3. 2487 Stock